عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
TT
TT

Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights

Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits.

The drug, also known as tirzepatide, reduced the risk of a composite of heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death by 38% compared to a placebo, according to Reuters.

The trial enrolled 731 patients across 10 countries who have heart failure with preserved ejection fraction and obesity.

The condition "accounts for nearly half of all heart failure cases, and in the US almost 60% of those impacted also live with obesity," Jeff Emmick, Lilly senior vice president, product development, said in a statement.

Lilly said the study also showed the drug significantly improved heart failure symptoms and physical limitations.

Heart failure is a condition in which the heart is unable to pump enough blood to meet the body's needs. It is associated with a high burden of symptoms and physical limitations affecting daily life, including fatigue, shortness of breath, reduced ability to exercise and swelling of extremities.

Trial patients on tirzepatide were given weekly injections of the highest dose they could tolerate, up to 15 milligrams, and were followed for a median of two years.

The drug led to 15.7% weight loss in the combined population of people with and without type 2 diabetes, compared with 2.2% for the placebo, Lilly said. For the non-diabetes patients, weight loss was 13.9%.

Zepbound, also sold under the brand name Mounjaro for type 2 diabetes, is part of a top-selling class of drugs designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow digestion and decrease appetite.

Lilly said the most common side effects for trial patients on tirzepatide were diarrhea, nausea, constipation and vomiting.

The company said it plans to submit the heart failure results to the US Food and Drug Administration and other regulatory agencies starting later this year. The findings will also be presented at an upcoming medical meeting and submitted to a peer-reviewed journal.

Novo Nordisk has reported data showing its GLP-1 weight loss drug Wegovy reduces heart failure symptoms.

Most Viewed

 
 
Varieties

2 Private Lunar Landers Head Toward the Moon in Roundabout Journey

The Blue Ghost Mission 1 on a SpaceX Falcon 9 rocket lifts off from NASA's Launch Complex 39A at the agency's Kennedy Space Center in Cape Canaveral, Florida, USA, 15 January 2025. EPA/CRISTOBAL HERRERA-ULASHKEVICH
The Blue Ghost Mission 1 on a SpaceX Falcon 9 rocket lifts off from NASA's Launch Complex 39A at the agency's Kennedy Space Center in Cape Canaveral, Florida, USA, 15 January 2025. EPA/CRISTOBAL HERRERA-ULASHKEVICH
TT
TT

2 Private Lunar Landers Head Toward the Moon in Roundabout Journey

The Blue Ghost Mission 1 on a SpaceX Falcon 9 rocket lifts off from NASA's Launch Complex 39A at the agency's Kennedy Space Center in Cape Canaveral, Florida, USA, 15 January 2025. EPA/CRISTOBAL HERRERA-ULASHKEVICH
The Blue Ghost Mission 1 on a SpaceX Falcon 9 rocket lifts off from NASA's Launch Complex 39A at the agency's Kennedy Space Center in Cape Canaveral, Florida, USA, 15 January 2025. EPA/CRISTOBAL HERRERA-ULASHKEVICH

In a two-for-one moonshot, SpaceX launched a pair of lunar landers Wednesday for US and Japanese companies looking to jumpstart business on Earth’s dusty sidekick.
The two landers rocketed away in the middle of the night from NASA’s Kennedy Space Center, the latest in a stream of private spacecraft aiming for the moon, The Associated Press reported. They shared the ride to save money but parted company an hour into the flight exactly as planned, taking separate roundabout routes for the monthslong journey.
It’s take 2 for the Tokyo-based ispace, whose first lander crashed into the moon two years ago. This time, it has a rover on board with a scoop to gather up lunar dirt for study and plans to test potential food and water sources for future explorers.
Lunar newcomer Texas-based Firefly Aerospace is flying 10 experiments for NASA, including a vacuum to gather dirt, a drill to measure the temperature below the surface and a device that could be used by future moonwalkers to keep the sharp, abrasive particles off their spacesuits and equipment.
Firefly’s Blue Ghost — named after a species of US Southeastern fireflies — should reach the moon first. The 6-foot-6-inches-tall (2-meter-tall) lander will attempt a touchdown in early March at Mare Crisium, a volcanic plain in the northern latitudes.
The slightly bigger ispace lander named Resilience will take four to five months to get there, targeting a touchdown in late May or early June at Mare Frigoris, even farther north on the moon’s near side.
“We don’t think this is a race. Some people say ‘race to the moon,’ but it’s not about the speed,” ispace’s founder CEO Takeshi Hakamada said this week from Cape Canaveral.
Both Hakamada and Firefly CEO Jason Kim acknowledge the challenges still ahead, given the wreckage littering the lunar landscape. Only five countries have successfully placed spacecraft on the moon since the 1960s: the former Soviet Union, the US, China, India and Japan.
“We’ve done everything we can on the design and the engineering,” Kim said. Even so, he pinned an Irish shamrock to his jacket lapel Tuesday night for good luck.
The US remains the only one to have landed astronauts. NASA’s Artemis program, the successor to Apollo, aims to get astronauts back on the moon by the end of the decade.
Before that can happen, “we’re sending a lot of science and a lot of technology ahead of time to prepare for that,” NASA's science mission chief Nicky Fox said on the eve of launch.
If acing their respective touchdowns, both spacecraft will spend two weeks operating in constant daylight, shutting down once darkness hits.
Once lowered onto the lunar surface, ispace’s 11-pound (5-kilogram) rover will stay near the lander, traveling up to hundreds of yards (meters) in circles at a speed of less than one inch (a couple centimeters) per second. The rover has its own special delivery to drop off on the lunar dust: a toy-size red house designed by a Swedish artist.
NASA is paying $101 million to Firefly for the mission and another $44 million for the experiments. Hakamada declined to divulge the cost of ispace’s rebooted mission with six experiments, saying it's less than the first mission that topped $100 million.
Coming up by the end of February is the second moonshot for NASA by Houston-based Intuitive Machines. Last year, the company achieved the first US lunar touchdown in more than a half-century, landing sideways near the south pole but still managing to operate.